RxDoctor Payments Data

Eva Vaishnav, DO

Cardiovascular Disease · Wilkes Barre, PANPI 1003259003

Payments from drug & device makers

$4,488in general payments, 2019–2025

Across 29 payments — averaging $154.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$3K
  • Abbott$2K
  • Abiomed$112
  • Pfizer$95
  • Cardiac Dimensions, Inc.$28
  • Irhythm Technologies, Inc.$20

What the payments were for

  • Speaking & faculty fees$2,25050%
  • Travel & lodging$1,32029%
  • Food & beverage$91820%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)11$2,562
Abbott12$1,671
Abiomed3$112
Pfizer1$95
Cardiac Dimensions, Inc.1$28
Irhythm Technologies, Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,488 in reported general payments places this provider in the 65th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$59,925
Medicare patients
852
Services billed
1,257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan324$282,201
JardianceEmpagliflozin131$121,392
EliquisApixaban89$75,543
FarxigaDapagliflozin Propanediol17$10,864
Metoprolol Succinate321$5,166
Torsemide173$4,671
Potassium Chloride53$2,190
Atorvastatin Calcium100$1,662
Spironolactone203$1,453
Eplerenone17$1,003
Furosemide104$980
Midodrine Hcl19$870
Carvedilol67$655
Losartan Potassium42$459
Amiodarone Hcl28$430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$95$75,54389 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Wilkes Barre

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →